Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 7/20 | 0.72 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.72 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 2/20 | 0.41 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.39 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.39 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.39 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.39 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10116875 | 0.96 | ESR1 (0.74) | ESR1ESR2HDAC1HDAC6HTT | |
| SCHEMBL15489484 | 0.94 | ESR1 (0.75) | ESR1ESR2HDAC1HDAC6HTT | |
| SCHEMBL2111934 | 0.85 | HTT (0.61) | ESR1ESR2HTTSMN1; SMN2MTOR | |
| SCHEMBL2113569 | 0.84 | ESR1 (1.00) | ESR1ESR2 | |
| SCHEMBL12318272 | 0.84 | ESR1 (0.86) | ESR1ESR2 | |
| SCHEMBL2114738 | 0.81 | ESR1 (0.77) | ESR1ESR2 | |
| SCHEMBL2112286 | 0.81 | ESR1 (0.67) | ESR1ESR2HTTSMN1; SMN2 | |
| SCHEMBL15491997 | 0.81 | ESR1 (0.67) | ESR1ESR2HTTKCNQ3KCNQ2 | |
| Gtx-758 SCHEMBL29420202 | 0.80 | ESR1 (1.00) | ESR1ESR2 | |
| Gtx-758 SCHEMBL2112794 | 0.80 | ESR1 (1.00) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9624161-B2 | Estrogen receptor ligands and methods of use thereof | GTX, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9427418-B2 | Estrogen receptor ligands and methods of use thereof | GTX, INC. (US) | 2016-08-30 | — | — | US | disclosed |
| US-9409856-B2 | Estrogen receptor ligands and methods of use thereof | GTX, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-20160031797-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | GTX, INC. | 2016-02-04 | — | — | US | disclosed |
| US-20150087712-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | GTX, INC. | 2015-03-26 | — | — | US | disclosed |
| US-20140187641-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | Gtx (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140171468-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | GTX, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140057985-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | Gtx (US) | 2014-02-27 | — | — | US | disclosed |
| US-20140057946-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | Gtx (US) | 2014-02-27 | — | — | US | disclosed |
| US-20120077845-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | GTX, INC. | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077845-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | GNRHR, LHCGR, SHBG | ESR1 21/4885ESR2 15/4885HDAC1 569/4885 |
| US-20140187641-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | SHBG, AR, NR5A1 | ESR1 26/4885ESR2 18/4885HDAC1 727/4885 |
| US-20140057985-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | SHBG, AR, LHCGR | ESR1 30/4885ESR2 20/4885HDAC1 476/4885 |
| US-20160031797-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | ESRRB, ESRRA, ESR2 | ESR1 7/4885ESR2 3/4885HDAC1 1922/4885 |
| US-20140057946-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | SHBG, AR, LHCGR | ESR1 30/4885ESR2 20/4885HDAC1 476/4885 |
| US-20140171468-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | SHBG, GNRHR, FSHR | ESR1 10/4885ESR2 9/4885HDAC1 2814/4885 |
| US-20150087712-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | SHBG, AR, NR5A1 | ESR1 26/4885ESR2 18/4885HDAC1 727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.